文献速递类风湿关节炎

早期类风湿关节炎中循环CD39+FoxP3+调节性T细胞的一过性升高可预测甲氨蝶呤的临床应答

Transiently increased circulating CD39+FoxP3+ Treg cells predicts the clinical response to methotrexate in early rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

研究纳入98例未经治疗的早期类风湿关节炎患者和98名健康对照,用流式细胞术检测循环CD39+FoxP3+调节性T细胞(cTreg39+)。起始甲氨蝶呤12个月后,达到低疾病活动度(DAS28-ESR≤3.2)的患者基线cTreg39+频率显著高于未达到者,基线cTreg39+切点42.0%预测12个月低疾病活动度的敏感度为90.4%、特异度为96.8%。

要点

  • 早期类风湿关节炎患者基线cTreg39+频率高于健康对照。
  • 基线cTreg39+频率高者12个月后更易达到低疾病活动度。
  • 基线cTreg39+切点42.0%预测12个月低疾病活动度:敏感度90.4%、特异度96.8%。

核心结论

  • 甲氨蝶呤与Treg39+细胞协同作用,基线cTreg39+频率可预测早期类风湿关节炎对甲氨蝶呤的应答。
  • 早期类风湿关节炎中基线cTreg39+频率的一过性升高可能为及时起始甲氨蝶呤提供窗口。

研究设计与样本

  • 研究纳入98例未经治疗的早期类风湿关节炎患者和98名健康对照,用流式细胞术检测新鲜分离的外周血淋巴细胞。
  • 起始甲氨蝶呤12个月后,82例患者进行临床再评估,其中40例重复流式细胞术检测。
  • 在Treg/Tresp共培养中评估甲氨蝶呤对Treg细胞功能的影响。

主要发现

  • 基线(0个月)cTreg39+细胞频率在早期类风湿关节炎中高于健康对照水平。
  • 12个月达到低疾病活动度(DAS28-ESR≤3.2)者(n=51)基线cTreg39+频率显著高于未达到者(n=31)。
  • 12个月时cTreg39+频率不再升高,但仍与疾病活动度相关:达到低疾病活动度者仍显著高于未达到者。
  • 体外实验中甲氨蝶呤增强Treg39+细胞功能,但对Treg39-细胞无影响。

关键数值与推荐

  • 基线cTreg39+预测12个月低疾病活动度(DAS28-ESR≤3.2)的切点为42.0%,敏感度90.4%,特异度96.8%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: A subset of human circulating FoxP3+ regulatory T cells expresses CD39 (cTreg39+) and hydrolyses pro-inflammatory adenine nucleotides released at inflammatory foci, releasing the anti-inflammatory agent adenosine. Methotrexate (MTX), inhibiting 5-aminoimidazole-4-carboxamide ribonucleotide transformylase, enhances the extrusion of adenine nucleotides and may help Treg39+ cells control inflammation. Therefore, we examined the relation of cTreg39+ cells with the effect of MTX in early rheumatoid arthritis (eRA). METHODS: Freshly isolated peripheral blood lymphocytes from 98 untreated eRA patients and 98 healthy controls (HC) were examined by cytometry. Twelve months (12 m) after initiating MTX, 82 patients were clinically re-evaluated and cytometry was repeated in 40 of them. The effect of MTX on Treg cell potency was assessed in Treg/Tresp cocultures. RESULTS: The baseline (0 m) cTreg39+ cell frequency was elevated in eRA above HC levels. Patients who reached low disease activity at 12 months (12 m-LDA, DAS28-ESR ≤ 3.2, n = 51) had presented with a significantly higher 0 m cTreg39+ frequency vs those who did not (n = 31). The 0 m cTreg39+ cutoff for attaining 12 m-LDA was 42.0% (sensitivity = 90.4%, specificity = 96.8%). At 12 m, the cTreg39+ frequency was no longer elevated but its association with disease activity remained: it was still significantly higher in patients who had reached LDA vs those who had not. In vitro, MTX augmented the Treg39+ cell potency but had no effect on Treg39- cells. CONCLUSION: MTX cooperates with Treg39+ cells and the baseline cTreg39+ frequency predicts the response to MTX in eRA. In addition, the transiently elevated baseline cTreg39+ frequency in eRA may provide a slot for prompt MTX initiation.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Villalba A, Nuño L, Benito-Miguel M, et al. Transiently increased circulating CD39+FoxP3+ Treg cells predicts the clinical response to methotrexate in early rheumatoid arthritis. Rheumatology (Oxford). 2025. PMID: 39141491. doi:10.1093/rheumatology/keae446

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。